This implies that passive immunization with tau antibodies is usually a viable therapeutic target and that the CSF volume of p-tau262/356 or from the microtubule binding domain (MTBD) can serve as a beneficial biomarker of tau pathology to watch tau therapeutics in medical trials.Within this assay, researchers include extracts from Alzheimer’s Mi